Journal
Journal of allergy and clinical immunology
Publication Date
2-1-2020
Volume
145
Issue
2
First Page
572
Last Page
582
Document Type
Open Access Publication
DOI
10.1016/j.jaci.2019.08.042
Rights and Permissions
Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME; INCB 18424-206 Study Investigators. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020 Feb;145(2):572-582. doi: 10.1016/j.jaci.2019.08.042. Copyright 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.jaci.2019.08.042
Recommended Citation
Kim, Brian S; Howell, Michael D; Sun, Kang; Papp, Kim; Nasir, Adnan; Kuligowski, Michael E; and INCB 18424-206 Study Investigators, "Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream." Journal of allergy and clinical immunology. 145, 2. 572 - 582. (2020).
https://digitalcommons.wustl.edu/oa_4/254
